CK14 Expression Identifies a Basal/Squamous-Like Type of Papillary Non-Muscle-Invasive Upper Tract Urothelial Carcinoma

Object: CK14 expression is an important marker of basal/squamous-like (BASQ)-type muscle-invasive bladder carcinoma, and this molecularly defined subtype has a poor prognosis and a distinct response to chemotherapy. However, CK14 expression and its clinicopathological and molecular significance in papillary non-muscle-invasive upper tract urothelial carcinoma (NMIUTUC) remain unknown. Herein, we investigated the prognostic implications of immunohistochemical (IHC) staining for CK14 and the transcriptional characteristics associated with CK14 expression in papillary NMIUTUC.

Materials and Methods: IHC staining for CK14 was conducted in 204 papillary NMIUTUC specimens. Positive CK14 IHC staining was defined as a positive signal in >0% of tumor cells. RNA sequencing data were analyzed from 8 papillary high-grade NMIUTUC specimens consisting of 4 CK14-positive and 4 CK14-negative tumors.

Results: CK14 positivity was associated with a high TNM stage (p < 0.001) and a high World Health Organization grade (p = 0.003). Survival analysis showed that CK14 positivity was significantly associated with poor progression-free survival (p = 0.015; hazard ratio [HR] = 2.990; 95% confidence interval [CI] = 1.180–7.580) and was marginally associated with poor cancer-specific survival (p = 0.052; HR = 3.77; 95% CI = 0.900–15.780). Gene set enrichment analysis demonstrated that the CK14-positive tumors were associated with a basal subtype of breast cancer, squamous cell carcinoma development, p40, tumor necrosis factor α-nuclear factor-κB, and p53 pathways, and embryonic stem cells; these characteristics are reminiscent of the BASQ subtype. In addition, with a p < 0.05 and |fold change| ≥2 as the cutoffs, we identified 178 differentially expressed genes when comparing CK14-positive and CK14-negative tumors. Functional analysis of these genes revealed several networks and gene ontology terms related to the positive regulation of cellular proliferation in CK14-positive tumors. Consistent with these results, we demonstrated that the mean Ki-67 proliferative index was higher in CK14-positive tumors than it was in CK14-negative tumors (2.3 vs. 0.8%, respectively, p = 0.002).

Conclusion: CK14-positive papillary NMIUTUC is an aggressive subtype with BASQ-like molecular characteristics and dynamic proliferative activity. We propose that CK14 IHC staining can be a useful biomarker of BASQ-type papillary NMIUTUC that can be applied in daily practice with the aim of precision oncology.

Introduction

Muscle-invasive bladder carcinoma (MIBC) is broadly classified into basal and luminal subtypes based on transcription profiles (1–5). The basal subtype shows basal/squamous/stem cell-like features: high expression of basal-type genes (KRT5, KRT6, KRT14, CD44, CDH3, TGM1, DSC3, MYC, and EGFR), low levels of luminal-type genes (KRT20, PPARG, GATA3, FOXA1, ERBB2, and UPKs), active signaling pathways [p63, c-myc, signal transducer and activator of transcription 3, and nuclear factor-κB (NF-κB)], and frequent squamous differentiation (1, 4, 6). In addition, basal-type MIBC has a worse prognosis than the luminal subtype, but it may respond well to cytotoxic chemotherapies (1, 7). Recently, it was also suggested that genetic subtypes of MIBC may determine susceptibility to immune checkpoint inhibitors (8, 9). However, the basal subtypes defined by various independent studies contain a diversity in detailed molecular and phenotypic characteristics. In an attempt to explore the common ground, therefore, a consensus was reached regarding the existence and the definition of the common basal/squamous-like (BASQ) subtype: MIBC with high expression of CK14 and CK5/6 but low expression of GATA3 and FOXA1 (10). Immunohistochemical (IHC) staining for these markers is a readily accessible technique that helps to standardize the assessment of the BASQ subtype (11, 12).

On the other hand, accumulating evidence demonstrates that non-muscle-invasive urothelial carcinoma has a clinical-pathological-genetic association that is distinct from (and occasionally even contradictory to) what has been characterized in MIBC. For example, Hedegaard and colleagues (13) demonstrated that the luminal-like (e.g., high KRT20/UPKs and low KRT5/CD44) gene expression cluster of non-muscle-invasive bladder carcinoma (NMIBC) had worse clinical outcomes than what was observed in the basal-like cluster. Different studies further support the association between luminal-like type and either advanced pathological states or short survival durations in NMIBC using CK5/6 (KRT5/KRT6) and CK20 (KRT20) as surrogate protein or mRNA markers (14–16). In line with these results when studying the urinary bladder, we previously reported that papillary non-muscle-invasive upper tract urothelial carcinoma (NMIUTUC) with luminal-like, CK5/6-negative/CK20-positive, or CD44-negative/CK20-positive, immunophenotypes had distinctly poor prognoses that were probably associated with altered cell adhesion and late cell cycle/proliferation functions (17, 18).

Despite these conflicting results observed regarding some of the subtype-defining markers in early urothelial carcinoma, high KRT14 levels were independently prognostic of poor survival both in NMIBC and in MIBC (19). CK14 is a type I acidic keratin that is expressed in mitotically active basal cells of the stratified epithelium, where it promotes proliferation, and differentiation and in turn supports structural integrity (20). As CK14-positive basal cells differentiate into umbrella cells in the normal urothelium, CK14 expression is reduced and replaced by CK20. Consistent with this observation, Volkmer et al. (19) and Ho et al. (21) demonstrated that CK14 defined the most primitive/least differentiated basal-type urothelial carcinoma, which preceded the emergence of cancer cells expressing CK5 (intermediately differentiated) or CK20 (well-differentiated); further, CK14 expression marked the highly tumorigenic stem cell population. The increase in CK14 immunoreactivity was also observed at an early carcinogenesis stage, initiating the appearance of malignant lesions of the urinary bladder in a rat model (22). Moreover, CK14-positive urothelial carcinoma cells might have a predilection for chemoresistance (23). In addition, CK14 was associated with a poor prognosis of other malignancies, including breast cancer, squamous cell carcinoma, and salivary gland carcinoma, because it triggers proliferation, dedifferentiation, invasion, and metastasis of these cancers (24–26). However, how CK14 overexpression regulates the progression of urothelial carcinoma has not been fully elucidated. Furthermore, because of the rarity of upper tract urothelial carcinoma, which accounts for only 5–10% of the total urothelial carcinoma (27), CK14 expression and its clinicopathological and molecular significance in papillary NMIUTUC has not been studied. Herein, we investigated the prognostic implications of IHC staining for CK14 in 204 papillary NMIUTUC specimens. In addition, we analyzed the transcriptional characteristics associated with CK14 expression in papillary NMIUTUC.

Materials and Methods

The clinical and prognostic significance of CK14 expression was determined in a prognosis cohort using IHC staining of tissue microarray (TMA) slides. Transcriptional characteristics associated with CK14 expression were evaluated in the high-grade GEP cohort composed of fresh-frozen NMIUTUC samples. As supplement, we subsidiarily assembled the low-grade NMIBC cohort using Lund urinary bladder data. This study was approved by the regional Institutional Review Board (H-1911-029-1077), and informed consent was waived by the Review Board.

Prognosis Cohort and TMA

Formalin-fixed paraffin-embedded blocks of 204 NMIUTUC specimens (195 radical nephroureterectomy and 9 ureterectomy) were collected from the pathologic archive of Seoul National University Hospital (prognosis cohort). Clinicopathological and follow-up data were obtained from medical records. The staging and grading evaluation followed the American Joint Committee on Cancer 8th TNM staging system and World Health Organization (WHO) 2004/2016 classification, respectively (28). Triplicate 2 mm cores of tumor area were utilized for TMA experiments (Superbiochips Laboratories, Seoul, Republic of Korea).

Immunohistochemical Staining

IHC staining for CK14 (1:300; LL002; Cell Marque Cat# 314M-14, RRID:AB_1159418, Rocklin, CA, US) and Ki-67 (1:100; MIB-1; Agilent Cat# M7240, RRID:AB_2142367, Santa Clara, CA, US) was conducted on 4-μm-thick TMA sections with a Benchmark autostainer (Ventana, Tucson, AZ, US), according to the manufacturer's instructions. IHC staining revealed that CK14 expression was variable and included the following patterns: absent, focal staining in a few tumor cells, immunoreactivity confined to the basal layer, or diffuse staining with or without occasional strong signal detected in the basal layer (Supplementary Figure 1). Because CK14 and Ki-67 stains are routinely conducted for diagnostic purposes in various organs and the staining protocols are firmly established, we did not use positive or negative controls. Considering the prognostic significance and sample distribution, immunoreactivity in >0% of tumor cells was defined as positive CK14 IHC staining (Supplementary Figure 2). Two pathologists (MJ and KCM) read the CK14 IHC slides. Intra/inter-observer variability was minimal due to the clear and straightforward staining result. The mean Ki-67 proliferative index (%) was quantitatively measured using QuPath (version 0.1.2) (29) on TMA slides that were virtually scanned (Aperio AT2, Leica Biosystem, Wetzlar, Germany). For 189 patients, IHC profiles for CK5/6 and CK20 were retrieved from our previous study (17). Briefly, positive CK5/6 and CK20 IHC staining was defined as >20 and >1%, respectively. CK5/6-other staining referred to either a positive expression or CK5/6 expression confined to the basal layer. CK20-other staining referred to either a negative reaction or CK20 expression that was restricted to umbrella cells.

Gene Expression Profile (GEP) Cohorts

GEP analysis in the context of CK14 protein expression was determined from RNA sequencing and CK14 IHC staining data from independent high-grade papillary NMIUTUC specimens, which were generated previously (18). In short, surgically resected fresh tumors were cut in half: one half was subjected to RNA sequencing using a HiSeq 2500 platform (Illumina, San Diego, CA, US), and the other half was embedded in paraffin blocks for evaluation of CK14 immunoexpression. According to the same cutoff criteria used for CK14 positivity (>0%), 4 CK14-positive and 4 CK14-negative high-grade papillary NMIUTUC samples were assembled as the high-grade GEP cohort.

In our RNA sequencing depository, there were too few CK14-positive low-grade papillary NMIUTUC specimens to analyze. Therefore, we used Lund urinary bladder carcinoma mRNA data (GSE32894) to determine GEP related to CK14 expression in papillary low-grade early urothelial carcinoma (5). Clinicopathological details and CK14 IHC expression of these samples were obtained from another source, as summarized in Supplementary Table 1 (30). The previous annotation “urothelial-like histology,” indicating clear separation between tumor and stroma and well-arranged tumor cells with homogenous nuclei, was tentatively accepted as a papillary architecture in NMIBC (30). Consequently, a low-grade NMIBC cohort (6 CK14-positive and 25 CK14-negative NMIBCs) was created with the following inclusion criteria: (1) stage Ta or T1, (2) grade 1 [WHO 1999 guideline (28)], and (3) “urothelial-like histology.” CK14 positivity (IHC tumor cell score >0) and negativity (IHC tumor cell score = 0) were designated as above (30). For these 31 cases, gene expression data were preprocessed according to previous methods (5). Differentially expressed genes (DEG)s between CK14-positive and CK14-negative tumors were analyzed in both the high-grade GEP cohort and low-grade NMIBC cohort.

Functional Enrichment and Network Analysis

Gene set enrichment analysis (GSEA) was performed against public gene sets (31). The networks and functional analyses were generated through the use of Ingenuity Pathway Analysis with a Benjamini-Hochberg false discovery rate (FDR) <0.05 as the cutoff (32). Based on the knowledge database, IPA determines local networks and functional terms that are particularly enriched for the input DEG sets. Gene ontology (GO) (33, 34) and Kyoto encyclopedia of genes and genomes (KEGG) (35) analyses were also performed. In addition, a Metascape membership search of GO themes was conducted, as previously described (36).

Statistics

The association between clinicopathological variables and IHC results was analyzed by Pearson's χ2-test with Yate's correction or Fisher's exact test. Progression-free survival (PFS) was defined as the interval between surgery and upper urinary tract recurrence or distant metastasis, or the last follow-up visit. Cancer-specific survival (CSS) was defined as the interval between surgery and cancer-related death or the last follow-up visit. Overall survival (OS) was calculated as the term between surgery and death or the last follow-up visit. Kaplan-Meier analyses with log-rank tests were used to compare survival. A Cox proportional hazards regression model was used to calculate the hazard ratio (HR) and confidence interval (CI) in univariate and multivariate analyses. A two-tailed p < 0.05 was considered statistically significant. All statistical analyses were performed with SPSS 25 (IBM, Armonk, NY) or R.

Results

Clinicopathological Association of CK14 IHC Staining

Clinicopathological details of patients in the prognosis cohort and their association with CK14 expression are summarized in Table 1. Briefly, the median age was 67 years (range, 29–95) at diagnosis, and the male-to-female sex ratio was 4.1:1. IHC staining for CK14 was positive in 139 (68.1%) patients and negative in 65 (31.9%) patients. CK14 positivity was associated with high (≥I) TNM stage (p < 0.001) and high WHO grade (p = 0.003). In addition, CK14 positivity was related to combined CK5/6-CK20 expression (p = 0.001), where CK5/6-negative/CK20-positive expression was more prevalent in CK14-positive tumors (45.8 vs. 23.8%).

TABLE 1

Table 1. Clinicopathological details of the prognosis cohort associated with CK14 expression.

Prognostic Implications of CK14 IHC Staining

In the survival analysis, CK14 positivity was significantly associated with poor PFS (p = 0.015; HR = 2.990; 95% CI = 1.180–7.580) and was marginally associated with poor CSS (p = 0.052; HR = 3.77; 95% CI = 0.900–15.780) and OS (p = 0.275; HR = 1.44; 95% CI = 0.750–2.760) (Figure 1). However, when adjusted for TNM stage, WHO grade and multifocality, CK14 expression failed to show significant association with PFS, while WHO grade and multifocality were independent prognostic factors of papillary NMIUTUC (Table 2).

FIGURE 1

Figure 1. Kaplan-Meier with log-rank test of CK14 IHC staining in PFS (A), CSS (B), and OS (C) of the prognosis cohort.

TABLE 2

Table 2. Multivariate analysis of progression-free survival.

Transcriptional Characteristics Associated With CK14 Expression

The median age of the high-grade GEP cohort was 67 years (range, 56–78) with a male-to-female sex ratio of 1.7:1. The renal pelvis/calyx (50%) and ureter (50%) were equally affected. One tumor was in stage pTa, and the other 7 tumors were in pT1. After exclusion of genes with 0 fragments in any sample, 15,395 genes were identified across the high-grade GEP cohort (Supplementary Data 1). GSEA demonstrated that CK14-positive tumors were associated with a basal subtype of breast cancer (FDR = 0.0), tumorigenesis of squamous cell carcinoma (FDR <0.001), the p40 (ΔNp63) pathway (FDR = 0.03), embryonic stem cell activities (FDR = 0.004), the tumor necrosis factor-α-NF-κB pathway (FDR = 0.002) and the p53 pathway (FDR = 0.002) (Figure 2). In addition, a poorly differentiated state of squamous cell carcinoma (FDR = 0.0), c-myc (FDR = 0.002), EGFR (FDR = 0.004), Wnt (FDR = 0.004), and mammalian target of rapamycin complex 1 (mTORC1) (FDR = 0.025) cascades, cell migration (FDR <0.001) and epithelial-mesenchymal transition (EMT) (FDR = 0.025) were also significantly associated with CK14 expression in high-grade papillary NMIUTUC.

FIGURE 2

Figure 2. Representative GSEA results enriched in CK14-positive tumors in the high-grade GEP cohort. NES, normalized enrichment score; FDR, false discovery rate; FWER, family-wise error rate; HNSCC, head and neck squamous cell carcinoma.

With a p < 0.05 and |fold change| ≥2 as the cutoffs, we identified 178 DEGs in the high-grade GEP cohort; of those identified, 103 and 75 genes were highly and lowly expressed, respectively, in CK14-positive tumors (Supplementary Figure 3A). KRT14 gene was highly expressed in CK14-positive tumors compared to CK14-negative tumors (fold change = 40.2, p = 0.035). IPA identified “cellular growth and proliferation” as one of the highest scored networks specifically related to CK14 expression (Figure 3A, Supplementary Figure 4). Other network-associated functions that were influenced by CK14 expression mainly included “cellular movement” and “cancer” (Table 3). IPA also identified significant enrichment of cellular movement/invasion and cell death functions, which were upregulated and downregulated, respectively, in CK14-positive tumors (Table 4). Consistent with these results, several GO and KEGG terms related to cell proliferation and cell component biosynthesis (e.g., “cell proliferation,” FDR <0.001; “positive regulation of gene expression,” FDR = 0.001), cell death (e.g., “cell death” and “apoptotic process”; both, FDR <0.001), adhesion (e.g., “cell adhesion” and “biologic adhesion”; both, FDR <0.001) and “pathways in cancer” (FDR <0.001) were identified (Figures 3B,C, Supplementary Table 2). Furthermore, GO themes related to proliferation (“cell proliferation,” “positive regulation of cell proliferation,” “epithelial cell proliferation,” and “regulation of epithelial cell proliferation”) were particularly enriched within the DEGs when compared to their representation within the human genome (p = 1.3 × 10⁻⁷) (Figure 3D).

FIGURE 3

Figure 3. DEGs in the high-grade GEP cohort that are involved in cellular growth and proliferation network, as revealed by IPA (A). Several GO-biologic process terms associated with proliferation were identified in the high-grade GEP cohort (blue) and the low-grade NMIBC cohort (orange) (B). Unsupervised clustering analysis of the DEGs included in the “cell proliferation” (GO: 0008283) GO term in the high-grade GEP cohort (C). Membership search of proliferation-related GO signatures enriched in the high-grade GEP cohort (D). The Ki-67 proliferative index is much higher in CK14-positive tumors than it is in CK14-negative tumors in the prognosis cohort (E).

TABLE 3

Table 3. Networks associated with CK14 positivity as assessed by Ingenuity Pathway Analysis.

TABLE 4

Table 4. Functional enrichment in CK14-positive tumors in the high-grade GEP cohort as assessed by Ingenuity Pathway Analysis.

A similar comparison of the low-grade NMIBC cohort identified 26 DEGs between CK14-positive and CK14-negative tumors. In unsupervised clustering analysis, all CK14-positive tumors and 3 CK14-negative tumors (UC_0041_2, UC_0240_1 and UC_0414_1) were grouped together by these DEGs (Supplementary Figure 3B). There was one gene (CLCA4) that was upregulated in CK14-positive tumors both in the high-grade GEP cohort and the low-grade NMIBC cohort. In agreement with the high-grade GEP cohort, cellular growth and proliferation overrepresented the biological functions associated with CK14 expression in the low-grade NMIBC cohort, as revealed by the IPA network search (Table 3, Supplementary Figure 5) and GO analysis (Figure 3B, Supplementary Table 2).

Next, we tried to validate the difference in cellular proliferation between CK14-positive and CK14-negative papillary NMIUTUC using Ki-67 IHC staining. CK14-positive tumors displayed a 2.3 ± 5.36% proliferative index (mean ± standard deviation), which was higher than 0.8 ± 2.06% index of CK14-negative tumors in the prognosis cohort (Mann-Whitney U, p = 0.002) (Figure 3E).

Discussion

In this study, we demonstrated that positive IHC staining for CK14 was associated with high-risk phenotypes of papillary NMIUTUC and was predictive for unfavorable survival rates. We compared CK14-positive and CK14-negative high-grade papillary NMIUTUC at the mRNA level to define a molecular framework underlying CK14 expression in papillary NMIUTUC. We found that CK14 positivity in papillary high-grade NMIUTUC marked transcriptional characteristics reminiscent of those in BASQ-type MIBC, including signatures of basal/stem cell and squamous cell carcinoma. This CK14-positive BASQ-like subtype was characterized by high proliferative functions in high-grade papillary NMIUTUC as well as in low-grade papillary NMIBC. IHC staining for Ki-67 verified a much higher proliferative activity in CK14-positive tumors than what was seen in CK14-negative papillary NMIUTUC.

There have been several seminal studies that uncovered genetically heterogeneous subclasses within MIBC via transcriptional clustering (1–5, 37). Of the subclasses, a common subtype, named the BASQ subtype, harbors a high level of basal-type genes, squamous-like features, and an aggressive phenotype (10). Although the BASQ subtype is a good foundation for MIBC evaluation, the applicability of BASQ markers (CK14, CK5/6, GATA3, FOXA1) to NMIUTUC or NMIBC has been questioned by us and others (13, 14, 16–18). For instance, CK5/6-negative/CK20-positive luminal-like papillary NMIUTUC had worse survival and was enriched with motility- and proliferation-associated genes (17, 18). In the same way, “class 2” NMIBC defined by Hedegaard and coworkers (13) was characterized by luminal-like genetic attributes, including low KRT5, KRT6, and CD44 expression and high GATA3, FOXA1, and KRT20 expression, but it had far worse survival than the other types of NMIBC. Moreover, this “class 2” subtype highly expressed KRT14 and genetic signatures related to late cell cycle, cancer stem cell phenotype and EMT, which was in accord with another report that found high CK14/KRT14 to be a determinant of poor NMIBC prognosis (19). In contrast to “class 2,” basal-like subtype “class 3” NMIBC was paradoxically shown to have a favorable prognosis, which probably reflected a dormant state (13). Consistent with these reports, we showed that CK14 positivity was associated with poor PFS in papillary NMIUTUC, which was in agreement with the characteristics of CK14-positive BASQ-type MIBC. Although the overall good prognosis of papillary NMIUTUC hindered the statistical significance of CK14 IHC staining in predicting CSS and OS in our study, Kaplan-Meier plots suggested that CK14 positivity also reached worse outcomes in CSS and OS. In addition, we demonstrated that CK14-positive papillary NMIUTUC had BASQ-like genetic features that were similar to those of basal-type breast cancer and those of squamous cell carcinoma (1, 2, 4, 38). Furthermore, CK14-positive papillary NMIUTUC shared other molecular hallmarks of BASQ-type MIBC: activated p40, c-myc, EGFR, and NF-κB pathways, which mediate growth and squamous differentiation of urothelial carcinoma. These observations further support the genetic similarity between CK14-positive papillary NMIUTUC and BASQ-type MIBC (1, 6, 38).

Network and functional enrichment analyses as well as Ki-67 IHC staining demonstrated that cellular growth and proliferative functions are particularly upregulated in CK14-positive papillary NMIUTUC, in accordance with previously reported high-risk phenotypes of NMIBC (13) and NMIUTUC (18). The DEGs associated with this function involved several oncogenes [e.g., CTBP2 (39), SNHG5 (40), RAB38 (41), ADM (42), ETV4 (43), EPHA2 (44), PTGES (45), FZD6 (46), ANXA2 (47), and STC1 (48)] and tumor-suppressor genes [e.g., EAF2 (49) and IKZF3 (50)], which were upregulated and downregulated, respectively, in CK14-positive tumors. Dysregulation of these genes modulates proliferation, survival, migration, EMT, or metastasis of urothelial carcinoma, and other malignancies, leading to poor prognoses of these tumors. Interestingly, some of these genes, such as ETV4, PTGES, CTBP2, FZD6, EAF2, and IKZF6, have not been implicated in urothelial carcinoma; thus, these genes are potential candidates for diagnostic, prognostic, and therapeutic biomarkers of urothelial carcinoma. In addition to cellular proliferation, functional analyses suggested that CK14-positive papillary NMIUTUC had increased invasion and migration activities. In early urothelial neoplasms, CK14 expression denotes a stem cell population of basal cells that harbor high mitotic activities and have self-renewal, tumorigenesis, and stromal invasion potential (21, 51). Likewise, varied transcription activators and activation pathways (e.g., p40, c-myc, NF-κB, EGFR, Wnt, and mTORC1 signaling pathways) that were enriched in CK14-positive papillary NMIUTUC are linked to proliferation and/or malignant transformation of basal cells and embryonal stem cells (21). For example, silencing of p40 inhibited c-myc-mediated proliferation of urothelial carcinoma, and high p63 expression was associated with poor prognosis in NMIBC (6, 21). Both EGFR-dependent cell growth and EGFR inhibitor-induced growth restriction were specific to the BASQ subtype in MIBC (38). CK14 expression may regulate the treatment response to cancer therapeutics, including chemotherapy, immunotherapy, and Bacillus Calmette-Guérin in urothelial carcinoma (1, 7–10, 19, 21, 52). Therefore, we hypothesize that CK14-positive papillary NMIUTUC is highly populated with proliferative cancer stem cells, which will potentially impact the treatment strategy.

Normal urothelium has a hierarchical structure of basal, intermediate, and umbrella cells with sequential differentiation that involve gradual changes in keratin profiles from CK14 to CK5 and/or to CK20; thus, these cells that are in different states supposedly can give rise to urothelial carcinomas with poor (CK14-positive/CK5-negative/CK20-negative), moderate (CK14-negative/CK5-positive/CK20-negative), and well (CK14-negative/CK5-negative/CK20-positive) differentiation, respectively (19, 21). The BASQ-like molecular subtypes defined in different studies, including the TCGA cluster III/IV, the Lund “urothelial-like B” subtype and the Lund “squamous cell carcinoma-like” subtype, exhibited poorly differentiated gene expression characteristics (10). Interestingly, poorly differentiated properties associated with CK14 positivity might be partially opposed by our finding that CK14 positivity was associated with luminal-like CK5/6-negative/CK20-positive expression in papillary NMIUTUC (17). The Lund “genomically unstable” subtype, which corresponds to a high-risk group of NMIBC, expresses low CK5 and high CK20, and is enriched with genetic signatures typical of urothelial differentiation and disrupted adhesion (5, 10, 14, 30). Similarly, low CK5/6 and high CK20 expression profiles were associated with high-risk phenotypes of both papillary NMIUTUC and NMIBC that exhibited altered adhesion, migration, and proliferation (13, 17, 18). Both CK14 and CK20 were suggested to direct the aggravation of early urothelial carcinoma via the carcinoma in situ-driven pathway (13, 17, 21). In an animal model, altered expression of CK14 and CK20 corresponded to an early tumorigenic step of papillary urothelial carcinoma (22). Taken together, it would be reasonable to speculate that CK5/6-negative/CK20-positive expression may represent a “second hit” to a primitive and aggressive CK14-positive papillary NMIUTUC. In other words, this putative CK14-positive/CK5/6-negative/CK20-positive expression might mirror a highly progressive CK14-positive urothelial carcinoma progeny, which remains to be explored (19). Furthermore, CK14, CK5/6, and CK20 expression would be valuable prognostic biomarkers in papillary NMIUTUC that appear to complement one another.

This study has some limitations. The number of patients included in the prognosis cohort was not enough to statistically discriminate CSS and OS in survival analysis. Second, the high-grade GEP cohort was relatively small, which introduced a risk of a biased estimation regarding molecular characteristics. Nevertheless, transcriptional profiles of CK14-positive papillary NMIUTUC were similar to those reported for the BASQ subtype, underscoring the appropriate representation of the high-grade GEP cohort. Finally, we applied array-based NMIBC mRNA data to infer transcriptional changes influenced by CK14 IHC staining in low-grade tumors. It is known that urothelial carcinoma of the upper and lower tract has high amount of overlap in transcriptomes, especially within early-staged tumors (53). However, the differences in tumor locations and analytic platforms prohibited deeper comparison of the high-grade GEP cohort and the low-grade NMIBC cohort. Further study incorporating enough samples of both low-grade and high-grade papillary NMIUTUC that exhibits positive CK14 IHC staining will be required.

In conclusion, CK14 positivity represents an aggressive BASQ-like subtype in papillary NMIUTUC that is enriched with brisk proliferative activity. CK14 IHC staining is a promising biomarker that can be applied in the management of non-muscle-invasive urothelial carcinoma in daily practice, with the aim of precision oncology.

Data Availability Statement

Publicly available datasets were analyzed in this study, these can be found in the NCBI Gene Expression Omnibus (GSE32894). The datasets generated for this study can be found in the Sequence Read Archive (SRA), PRJNA609154.

Ethics Statement

The studies involving human participants were reviewed and approved by Institutional Review Board of Seoul National University Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author Contributions

MJ and KM designed and performed the experiments. IJ, KK, and MJ analyzed the data. MJ wrote the manuscript. KM supervised the entire process.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number 2018R1D1A1B07045763).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.00623/full#supplementary-material

References

1. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. (2014) 25:152–65. doi: 10.1016/j.ccr.2014.01.009

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. (2014) 111:3110–5. doi: 10.1073/pnas.1318376111

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. (2017) 171:540–56.e25. doi: 10.1016/j.cell.2017.09.007

PubMed Abstract | CrossRef Full Text | Google Scholar

4. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. (2014) 507:315–22. doi: 10.1038/nature12965

CrossRef Full Text | Google Scholar

5. Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. (2012) 18:3377–86. doi: 10.1158/1078-0432.CCR-12-0077-T

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, et al. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS ONE. (2012) 7:e30206. doi: 10.1371/journal.pone.0030206

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. (2017) 72:544–54. doi: 10.1016/j.eururo.2017.03.030

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. (2016) 387:1909–20. doi: 10.1016/S0140-6736(16)00561-4

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. (2017) 18:312–22. doi: 10.1016/S1470-2045(17)30065-7

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer. (2016) 2:37–47. doi: 10.3233/BLC-150037

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Yuk HD, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH. Clinical outcomes of muscle invasive bladder cancer according to the BASQ classification. BMC Cancer. (2019) 19:897. doi: 10.1186/s12885-019-6042-1

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Sjodahl G, Eriksson P, Lovgren K, Marzouka NA, Bernardo C, Nordentoft I, et al. Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases. Mod Pathol. (2018) 31:1869–81. doi: 10.1038/s41379-018-0096-5

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. (2016) 30:27–42. doi: 10.1016/j.ccell.2016.05.004

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Patschan O, Sjodahl G, Chebil G, Lovgren K, Lauss M, Gudjonsson S, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol. (2015) 68:824–32. doi: 10.1016/j.eururo.2015.02.021

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. (2000) 13:1315–23. doi: 10.1038/modpathol.3880241

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, et al. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch. (2017) 470:267–74. doi: 10.1007/s00428-017-2064-8

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Jung M, Kim B, Moon KC. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma. Histopathology. (2019) 74:483–93. doi: 10.1111/his.13763

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Jung M, Lee JH, Kim B, Park JH, Moon KC. Transcriptional analysis of immunohistochemically defined subgroups of non-muscle-invasive papillary high-grade upper tract urothelial carcinoma. Int J Mol Sci. (2019) 20:570. doi: 10.3390/ijms20030570

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci USA. (2012) 109:2078–83. doi: 10.1073/pnas.1201493109

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Alam H, Sehgal L, Kundu ST, Dalal SN, Vaidya MM. Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells. Mol Biol Cell. (2011) 22:4068–78. doi: 10.1091/mbc.e10-08-0703

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Ho PL, Kurtova A, Chan KS. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol. (2012) 9:583–94. doi: 10.1038/nrurol.2012.142

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Gil da Costa RM, Oliveira PA, Vasconcelos-Nobrega C, Arantes-Rodrigues R, Pinto-Leite R, Colaco AA, et al. Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis. Int J Exp Pathol. (2015) 96:319–25. doi: 10.1111/iep.12145

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. (2015) 517:209–13. doi: 10.1038/nature14034

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci USA. (2016) 113:E854–63. doi: 10.1073/pnas.1508541113

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Gao XL, Wu JS, Cao MX, Gao SY, Cen X, Jiang YP, et al. Cytokeratin-14 contributes to collective invasion of salivary adenoid cystic carcinoma. PLoS ONE. (2017) 12:e0171341. doi: 10.1371/journal.pone.0171341

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Dmello C, Sawant S, Alam H, Gangadaran P, Mogre S, Tiwari R, et al. Vimentin regulates differentiation switch via modulation of keratin 14 levels and their expression together correlates with poor prognosis in oral cancer patients. PLoS ONE. (2017) 12:e0172559. doi: 10.1371/journal.pone.0172559

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Siegel RL, Miller KD, Jemal A. Cancer statistics, (2017) CA Cancer J Clin. (2017) 67:7–30. doi: 10.3322/caac.21387

CrossRef Full Text | Google Scholar

28. Cheng L, MacLennan GT, Lopez-Beltran A. Histologic grading of urothelial carcinoma: a reappraisal. Hum Pathol. (2012) 43:2097–108. doi: 10.1016/j.humpath.2012.01.008

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. (2017) 7:16878. doi: 10.1038/s41598-017-17204-5

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol. (2013) 183:681–91. doi: 10.1016/j.ajpath.2013.05.013

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. (2005) 102:15545–50. doi: 10.1073/pnas.0506580102

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. (2014) 30:523–30. doi: 10.1093/bioinformatics/btt703

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. the gene ontology consortium. Nat Genet. (2000) 25:25–9. doi: 10.1038/75556

PubMed Abstract | CrossRef Full Text | Google Scholar

34. The Gene Ontology C. The gene ontology resource: 20 years and still going strong. Nucleic Acids Res. (2019) 47:D330–D8. doi: 10.1093/nar/gky1055

CrossRef Full Text | Google Scholar

35. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. (2000) 28:27–30. doi: 10.1093/nar/28.1.27

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. (2019) 10:1523. doi: 10.1038/s41467-019-09234-6

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Aine M, Eriksson P, Liedberg F, Sjodahl G, Hoglund M. Biological determinants of bladder cancer gene expression subtypes. Sci Rep. (2015) 5:10957. doi: 10.1038/srep10957

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C, Chapeaublanc E, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. (2014) 6:244ra91. doi: 10.1126/scitranslmed.3008970

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Liu X, Yao N, Qian J, Huang H. High expression and prognostic role of CAP1 and CtBP2 in breast carcinoma: associated with E-cadherin and cell proliferation. Med Oncol. (2014) 31:878. doi: 10.1007/s12032-014-0878-7

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Ma Z, Xue S, Zeng B, Qiu D. lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27. Oncol Lett. (2018) 15:1924–30. doi: 10.3892/ol.2017.7527

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Tian DW, Liu SL, Jiang LM, Wu ZL, Gao J, Hu HL, et al. RAB38 promotes bladder cancer growth by promoting cell proliferation and motility. World J Urol. (2019) 37:1889–97. doi: 10.1007/s00345-018-2596-9

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Liu AG, Zhang XZ, Li FB, Zhao YL, Guo YC, Yang RM. RNA interference targeting adrenomedullin induces apoptosis and reduces the growth of human bladder urothelial cell carcinoma. Med Oncol. (2013) 30:616. doi: 10.1007/s12032-013-0616-6

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer. (2017) 17:337–51. doi: 10.1038/nrc.2017.20

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, et al. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res. (2006) 12:353–60. doi: 10.1158/1078-0432.CCR-05-1505

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Wang T, Jing B, Sun B, Liao Y, Song H, Xu D, et al. Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE2 signaling. Am J Cancer Res. (2019) 9:1145–60.

PubMed Abstract | Google Scholar

46. Corda G Sala A. Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage. Oncogenesis. (2017) 6:e364. doi: 10.1038/oncsis.2017.69

CrossRef Full Text | Google Scholar

47. Liu X, Ma D, Jing X, Wang B, Yang W, Qiu W. Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis. Med Oncol. (2015) 32:392. doi: 10.1007/s12032-014-0392-y

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Cai S, Liu L, Wang C, Zhang H, Wu W, Yang H, et al. Stanniocalcin-1 relates to tumor recurrence and unfavorable prognosis of urothelial bladder cancer. Int J Clin Exp Pathol. (2016) 9:5429–36.

Google Scholar

49. Guo W, Keener AL, Jing Y, Cai L, Ai J, Zhang J, et al. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells. Prostate. (2015) 75:976–87. doi: 10.1002/pros.22982

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Wu YM, Hu W, Wang Y, Wang N, Gao L, Chen ZZ, et al. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis. Breast Cancer Res Treat. (2013) 141:23–32. doi: 10.1007/s10549-013-2664-1

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA. (2009) 106:14016–21. doi: 10.1073/pnas.0906549106

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, et al. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res. (2010) 3:1235–45. doi: 10.1158/1940-6207.CAPR-10-0035

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Sanford T, Porten S, Meng MV. Molecular analysis of upper tract and bladder urothelial carcinoma: results from a microarray comparison. PLoS ONE. (2015) 10:e0137141. doi: 10.1371/journal.pone.0137141

PubMed Abstract | CrossRef Full Text | Google Scholar